Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemia·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Colonization with extended-spectrum and AmpC β-lactamase-producing Enterobacterales and bacteremia risk in patients with acute leukemia who receive induction chemotherapy without fluoroquinolone prophylaxis.

Antimicrobial agents and chemotherapy·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

The New England journal of medicine·2026
Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Related Experiment Video

Updated: May 6, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K

Standardizing the initial evaluation for myelodysplastic syndromes.

Danielle Marshall1, Gail J Roboz

  • 1Department of Medicine, Weill Medical College of Cornell University, 515 E. 71st Street, "S" Building, Room S262, New York, NY, 10021, USA, Dzm2008@med.cornell.edu.

Current Hematologic Malignancy Reports
|November 2, 2013
PubMed
Summary
This summary is machine-generated.

Diagnosing myelodysplastic syndromes (MDS) is challenging due to disease complexity. Optimizing initial patient evaluation with standard methods and emerging technologies is crucial for accurate diagnosis and treatment.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K

Related Experiment Videos

Last Updated: May 6, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Myelodysplastic syndromes (MDS) present diagnostic challenges due to heterogeneity and overlapping features with other conditions.
  • Accurate diagnosis relies on medical history, peripheral blood/bone marrow review by hematopathologists, and risk stratification using morphology, lab results, and cytogenetics.

Purpose of the Study:

  • To emphasize the critical need for optimizing the initial evaluation of patients with suspected myelodysplastic syndromes.
  • To highlight the importance of a standardized approach in the face of increasing MDS incidence and prevalence worldwide.

Main Methods:

  • Review of current diagnostic practices for suspected myelodysplastic syndromes.
  • Discussion of emerging technologies such as multi-color flow cytometry, FISH, and next-generation sequencing.

Main Results:

  • The current diagnostic pathway involves comprehensive clinical and pathological assessment.
  • Advanced technologies are showing promise for refining diagnosis, prognosis, and potentially treatment of MDS.

Conclusions:

  • Optimizing the initial evaluation of suspected MDS is essential for accurate diagnosis, risk stratification, and timely treatment.
  • Integrating emerging technologies with standard diagnostic methods will improve patient outcomes for myelodysplastic syndromes.